about
Genomic organization of the human gene HEP27: alternative promoter usage in HepG2 cells and monocyte-derived dendritic cellsMolecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiationLiposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study.Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.Ifosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide.A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.[Hemolytic anemias in adults].Measurement of immature platelets with Abbott CD-Sapphire and Sysmex XE-5000 in haematology and oncology patients.Immature platelets do not reliably predict platelet recovery in patients with intensive chemotherapy or stem cell transplantation.Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure.Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.Active DNA demethylation in human postmitotic cells correlates with activating histone modifications, but not transcription levelsTreatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry.Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin's lymphoma: final analysis of the HD12 tDistinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.Karyotype complexity and prognosis in acute myeloid leukemia.Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantationSecondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV.Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome.Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and OncolIsolated late metastasis from testicular seminoma presenting as a parotid gland mass: case report and review of the literature.Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study).CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs.Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.Prophylactic application of nebulized liposomal amphotericin B in hematologic patients with neutropenia.Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial.Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, Aspergillus PCR, multifungal DNA-microarray, and Aspergillus azole resistance PCRs in blood and bronchoalveolar lavage samples: resuThe JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis.Structure of the human carboxypeptidase M gene. Identification of a proximal GC-rich promoter and a unique distal promoter that consists of repetitive elements.Regulation of cellular retinoic acid binding protein (CRABP II) during human monocyte differentiation in vitro.Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.Human monocytes induce a carcinoma cell line to secrete high amounts of nitric oxide.Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML.Topotecan plus cyclophosphamide in adults with relapsed or refractory pediatric-type sarcoma: a retrospective analysis from the German Sarcoma Medical Oncology Group (AIO).
P50
Q24294103-64F7257D-EAA6-4BEC-89F9-F12039EDA98DQ28245478-A81866D9-EDE9-4A88-931E-ECC3E696D66CQ28298468-3F34E42C-926A-4209-9753-AA27F5F83EE5Q30313598-AFA56D22-1919-44B0-A1F4-7E4457329A9CQ30315150-86BC9E62-2147-4C21-B71E-B2A5BA5C5D2CQ30891587-B115263E-101E-4B7A-8781-7C3105E8262CQ33375131-768ED781-DD7D-4FB4-90BF-5922C4A3A54BQ33388189-0AB9678D-F1C8-453C-95EA-ABC16002B126Q33397960-D9FCA512-2B16-4696-AE33-BD536EEFA93FQ33408641-37AEE6DC-ECA5-4C5C-B385-7A3876999163Q33438699-B5117913-489D-4781-869D-A06A6E5FB4C9Q33440690-09B3343E-60DC-41B4-B4D8-8A1FC6873E5DQ33729437-9267BBF6-6345-4BDD-8F54-A7AF7E2291D3Q34024482-F4AD6F55-71FB-4532-A479-09269C45BC3BQ34112470-DEC6331F-BBF3-43AF-AA5F-12EF80EF1438Q34632951-CC5C671D-66F3-477C-A489-D0D941DCADF5Q36036294-96286979-4B02-4A1E-A46D-B99114750F45Q36070796-6A90A739-62ED-4A08-80D7-9DC9974AC078Q36548075-954A07CB-114D-459B-8065-5AB78EE02CA4Q36805865-507442A0-9912-4669-8617-A8888C9FBFE0Q36974374-07397F27-7F0B-4CF2-82E9-87DA5FC021D3Q37344532-D794340A-E112-4A2C-94F4-9AF3F9562E65Q37469835-714B39AE-3F87-4B46-B5D5-220CC46177A2Q37560732-4FA8CED6-CED0-4326-8AB1-E94B34B41E1CQ38081793-006CDF70-22F8-4EFD-BB79-4D2CC5C84F31Q38125675-2D4D8426-113C-417D-9C31-990832B4C1D1Q38222029-7171580F-8F4A-4CE6-9A6D-2E0589F9D2D9Q38795502-64DA3CE9-D094-419D-B7BB-0AFADDC0D69AQ38992830-C941B67B-8017-4ED1-AC2E-9E7EA0740C11Q40262923-1DC41E42-469B-41EE-B3BC-89CC8F18D412Q40324756-7618ECD7-C029-4A26-9417-627A5C8C4B9BQ40503352-DB7F940F-1B89-4B6C-B756-C04781646898Q40620405-B7E7971A-80FF-4821-9FC7-744CD17ADC6AQ40637471-A210ABD1-4068-4F52-A77F-7420280EFF1EQ40745050-BC0704F9-D639-4FF1-92BD-39BAA6F899FBQ41016566-F2CD620C-6374-4FDD-BCF5-56A970A8BDFAQ41161466-6A903678-C3EA-49D4-BA11-72D7DF5ED4A6Q41172610-6B6DBED7-1E06-4CA8-8F72-6FAB0C2BF698Q41345743-C74F6EC1-60B9-427C-AF35-9F283E3D1A58Q41595940-1123EE56-27EB-4C3A-A5E6-B990A23ECA8F
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stefan W. Krause
@ast
Stefan W. Krause
@en
Stefan W. Krause
@es
Stefan W. Krause
@nl
type
label
Stefan W. Krause
@ast
Stefan W. Krause
@en
Stefan W. Krause
@es
Stefan W. Krause
@nl
prefLabel
Stefan W. Krause
@ast
Stefan W. Krause
@en
Stefan W. Krause
@es
Stefan W. Krause
@nl
P106
P21
P31
P496
0000-0002-5259-4651